Spectral AI, Inc. (MDAI) Earnings Call Transcript
November 10, 2026
Earnings Call Speaker Segments
Thank you, Gary. Good afternoon, everyone, and thanks for being with us on Spectral AI's conference call covering financial results for the third quarter of 2026. Joining us today are Vincent Capone, our Chief Executive Officer, and David McGuire, our Chief Financial Officer. Before we get started, I want to remind all of you that some statements on this call are forward-looking statements as defined under the Safe Harbor provisions of the United States Private Securities Litigation Reform Act of 1995, including statements about the company's strategy, plans, objectives, initiatives, and financial outlook. In this call, terms such as "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose," along with variations of these words or similar expressions, or their negatives, are meant to identify forward-looking statements. Such forward-looking statements do not guarantee future performance, conditions, or results, and they carry a number of known and unknown risks, uncertainties, assumptions, and other important factors, many beyond the company's control, that might cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Listeners are therefore cautioned against placing undue reliance on any forward-looking statements. Investors should carefully weigh the foregoing factors as well as other risks and uncertainties described in the Risk Factors section of the company's SEC filings. Those filings identify and address additional important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. With that, I'd like to hand the call over to Vincent Capone, Spectral AI's Chief Executive Officer. Vince, please go ahead.
Thanks, Devin. I appreciate everyone being with us today. This afternoon we put out our earnings release, and it has more detail on how our operations performed; the 10-Q will go to the SEC on or before November 16th of this year. Results for the third quarter show Spectral AI continuing its shift from an R&D-focused organization into a commercial enterprise. Bringing a new medical technology to market takes more than a regulatory green light. It takes building clinical confidence, growing the relationships we already have with top burn centers, proving economic value to hospital systems, and in the end getting this technology woven into the clinical workflow. Those are exactly the areas our team is concentrated on. Progress with the initial BARDA-funded installations of DeepView AI has been solid, and that puts us on the path toward our first commercial sales—something we continue to view as achievable in 2026. In line with that, during the quarter we began manufacturing the initial 30 DeepView AI units destined for BARDA-supported rollouts at U.S. burn centers. Interest from burn centers nationwide has been encouraging, and our national sales footprint is taking shape. The clinical infrastructure, relationships, and evidence we are putting together at this stage, in our view, are essential to a commercial business that endures and expands. Our vision goes past merely putting devices into hospitals or burn centers for mass casualty preparedness. Preparedness is still an important piece of our strategy, but we think the far bigger opportunity lies in offering this technology as part of the clinical protocol for routine burn care. For our DeepView AI system, we want to build a national sales footprint that enables burn wound assessments to be more consistent, more objective, and more timely, with the ultimate aim of better patient outcomes. In our view, patients ought to be able to get the benefits of our advanced diagnostic technology no matter where they live or which burn center they go to. We're concentrating on bringing this technology to patients on a wide scale, no matter where they live or what their economic circumstances are, aiming to support more equitable availability of sophisticated burn wound evaluation and top-tier care. Under that approach, we've launched clinical trials in both the United States and the United Kingdom. In the U.K., we're self-funding a trial aimed at broadening our label so it covers burns to the head, hands, and feet; every site initiation visit has been finished across four U.K. burn centers, and enrollment has already reached 10 patients in this label expansion study. Here in the US, we're finishing up the groundwork for a study of our triage and treatment algorithm — the TNT study, as we refer to it — to further back the economic growth of our DeepView AI system. That trial is going to evaluate how DeepView AI might boost surgical accuracy, accelerate decisions about treatment, and cut down on time patients spend in the hospital. Our expectation is to launch TNT at four to five burn centers in early December of this year, and our plan is to expand it to 12 centers across the United States by the end of the first quarter of 2027. In building out how we commercialize this, we recognize that reimbursement matters a great deal economically, both for hospital systems and for physicians. So we've put in diligent effort to secure higher-level reimbursement coding for use of our device in inpatient and outpatient settings alike. In the early part of the third quarter, we submitted an application for a New Technology Add-on Payment, or NTAP, to the Centers for Medicare & Medicaid Services, and that application covers our DeepView system. If it gets approved, hospitals would get extra Medicare reimbursement for eligible uses of the DeepView system, and that would help bring down adoption barriers for eligible health systems and make integrating and using our device in the appropriate inpatient setting simpler. We expect a determination by August of next year. Regarding physicians, we'd point out that a reimbursement pathway has moved forward effective January 1st, 2027, with pricing backed by local Medicare Administrative Contractor rates. On our CPT 3 coding, we're working toward transitioning it to a CPT 1 code, and our TNT study will support that. We're also continuing to broaden the total body surface area burn calculation, which leverages the imaging and AI platform of our DeepView system to rapidly and objectively measure the proportion of a patient's body that has been burned. The improvements we're pursuing will deliver a standardized, data-driven input for triage, fluid resuscitation, and treatment decisions — particularly valuable in complex or mass casualty situations. Regarding our international sales plans, we continue to work on renewing the UKCA burn assessment approval we obtained in 2024 so that it incorporates the enhanced algorithm, hardware, and software covered by our FDA clearance this past May. While we had hoped to secure that clearance by year-end, we now anticipate receiving it in early 2027. Once we have it, we will begin initial sales and placements of the DeepView AI system in the UK, Australia, or the Gulf Cooperation Council countries; we also believe our established ties with leading burn centers worldwide will help support the first commercial launch outside the United States. So far, we have made solid progress. On the awareness front, the conversations we had at September's Southern Regional Burn Conference left us feeling upbeat. There, prominent burn surgeons shared findings from fresh research on our DeepView AI system. Their talks covered how accurately physicians spot burns that aren't healing, and also how consistently and reliably the DeepView system's AI analysis performs. On top of that, October saw us put the DeepView AI system on display at the American College of Emergency Physicians Scientific Assembly in Chicago. That gave us one more chance to showcase our technology, talk about what part it might play in burn assessment, and get direct input from emergency physicians on the clinical needs they face and the ways our device meets them. The way the development work pays off isn't the same as what drives the commercial side we're building, but our balance sheet still leaves us plenty of room to pursue our strategic commercial goals. We ended the quarter holding more than $11 million in cash, with debt we can comfortably handle, plus the ability to draw as much as $90 million more in non-dilutive funding through BARDA. While we transform from a research outfit into a business centered on commercialization, we remain careful in how we put capital to work and in the way we finance both the company and its expansion. We know what we need to focus on in the near term. First, we'll complete initial production and begin the first deliveries supported by BARDA of the DeepView AI system on a nationwide basis. Second, we'll expand commercial sales activity both domestically and internationally, leveraging current relationships and aiming for first sales in the U.S. and abroad. Third, we aim to continue assisting clinicians as they evaluate DeepView AI and integrate it into their clinical workflow. And fourth, we'll keep advancing our reimbursement and label expansion work to support hospitals and physicians. With that said, I'm pleased to turn the call over to our Chief Financial Officer, David McGuire.
Thanks for that, Vince. Before I get into the numbers, I want to give you some context on where things stand with BARDA. BARDA has provided roughly $250 million in non-dilutive funding for the development of DeepView AI, and that effort led to FDA de novo authorization this May; in June we wrapped up the base phase of our BARDA contract and shifted into the follow-on development phase. That phase has a smaller scope focused on specific development projects, and the two sides share the costs. BARDA reimburses us for part of our development costs, and we cover the remainder. Q3 was our first full quarter in that phase, and as we mentioned last quarter, we had prepared for it. Research and development revenue for the third quarter of 2026 came to $2.9 million, a decline of 24.7% from $3.8 million in Q3 2025. BARDA accounted for $2.7 million, compared with $3.4 million, which reflects both the narrower scope and the cost-sharing arrangement. Revenue from other U.S. government programs, mainly the MTEC handheld device program, was $0.1 million versus $0.4 million, since work on that program has now finished. Gross margin was 27.2%, down from 42.7%, which reflects our share of development costs with BARDA, recorded in cost of revenue. Total operating expenses for Q3 2026 were down 4%, to $4.7 million from $5.0 million in Q3 2025. We're still investing in commercialization while keeping a firm handle on costs, and we're doing so without compromising our ability to execute. Looking at OpEx by category for Q3 2026 versus Q3 2025, R&D expense rose to $2.0 million from $1.5 million, driven largely by the UK label expansion study for burns of the heads, hands, and feet that Vince discussed. G&A expense dropped to $2.3 million from $3.1 million, primarily on lower legal fees and related professional services. Selling and marketing expense rose by about $50,000 to $0.4 million, reflecting increased activity ahead of first commercial sales. For Q3 2026, other income was $0.2 million, compared with other expense of $0.2 million in Q3 2025. The primary factor was an $0.8 million gain related to the change in fair value of our warrant liabilities, partially offset by $0.6 million of net interest expense, mostly on our Avenue facility. We recorded a net loss of $3.7 million, or 11 cents per basic and diluted share, compared with $3.6 million, or 13 cents per share, in Q3 2025. Adjusted EBITDA, a non-GAAP measure, showed a loss of $3.7 million versus a loss of $3.1 million, reflecting lower gross profit, partly offset by those reduced operating expenses. As of September 30th, 2026, cash was $11.2 million, down from $15.4 million on December 31st, 2025. During the first nine months of the year, operating activities used $10.5 million, offset by $6.3 million from financing activities, chiefly the second tranche of our Avenue facility. That facility is now fully drawn to $15 million, has interest-only payments through March 2027, and comes due in March 2028. At the close of the quarter, 32.2 million shares were outstanding. Now for guidance: we're changing our 2026 research and development revenue outlook to about $13 million, versus the roughly $18.5 million we had previously guided to. Two things are mainly behind this change. First, the MTEC program is finished now, so there won't be any further contracting possibilities in 2026. Second, revenue shifts into later periods within the contract term already in place, because of how the timing works for development activities reimbursed under the BARDA contract. This guidance doesn't include revenue from DeepView AI device sales or from any new or extended government awards. As we head toward the initial placements Vince discussed, we're concentrating our portion of cost-share development on the features we think will hold the greatest commercial value. Under our commercial model, device purchases or leases are paired with recurring software and service revenue through agreements carrying a minimum term of three years. We think commercial sales can produce higher margins than our development work, and that this edge will grow as our installed base expands and recurring revenue builds. That compares with $0.11 per basic and diluted share, and $0.13 per share in Q3 2025. With that, I'll turn things over to the operator to open the floor for questions.
Great. Hey, Vince and David. Good afternoon, both of you. I'd like to open with a question about the New Technology Add-on Payment. I want to get a clearer picture of how that operates and what the incentive could be. I believe you mentioned it applies to hospitals. Are there other entities that can access it as well? Is it dependent on the type of patients they have? And are burn centers covered too? Also, do you have any sense of how large that payment might be for those providers?
John, thanks for asking. We were very pleased to submit our NTAP application in October. We had actually advocated for reimbursement tied to this New Technology Add-on Payment for hospital systems. It's not primarily for physicians. It's solely for the hospital system. We had requested a reimbursement code at $2,750 per patient. I think we feel fairly confident about how that NTAP coding will be resolved, but we don't have an answer yet. It will be resolved in August of 2027, with a two to three-year term starting in October of 2027 for the application and that additional payment. That comes on top of any payments the hospital system can generate through use of the device, both inpatient and, again, if they see them in the emergency department on an outpatient basis.
All right. So as you move toward commercialization and your team starts getting out into the field, what kinds of hurdles are you running into when it comes to landing those initial deployments and getting DeepView installed?
Great question. One of the points we try to emphasize is that what we're attempting here isn't ordinary — we're aiming at something extraordinary. I believe this technology is extraordinary in what it lets us do: actually sit there and diagnose burn tissue. For us, I see it as a chance to figure out how we can navigate the procurement process at burn centers and hospital systems. Getting through procurement has been roughly what we expected. We give centers the option to buy the device or lease it across a minimum three-year period. I think both of those approaches have shown some traction. From our standpoint, it's a chance to provide the strongest economic modeling to profitable centers and to community-focused centers — no matter your socioeconomic status, no matter where in the United States you're located, urban or rural, you'll have the same access to outstanding, groundbreaking technology across the country. To get right to your question, we've seen the procurement opportunities that come up for us. It simply comes down to us working through that at every one of the burn centers and hospital systems to get through the process. We've actually made solid progress, and we keep seeing opportunities open to us in 2026.
Alright. Over the past couple of months, you've been at quite a few medical conferences. You brought that up on the call as well. So what takeaways do you have from those? What kinds of interactions have you had with the people attending?
The reception has been quite good, I'd say; we've gained from both of our burn studies, the burn treatment study as well as the burn validation study, and now we're starting our TNT, our triage and treatment study; we have ties with several burn centers around the country. For us, the relationship and the reception have been excellent. Now it's simply a question of working through those centers and getting the devices placed there, so we can lay out a strategic, national sales footprint, both to support patient outcomes and to support mass casualty or countermeasure preparedness.
Do you think those conferences—the three or four you've had—have worked well as lead generators?
I'd say they've been useful for us. We've built relationships with quite a few different burn centers. Only a handful remain unfamiliar with us or with the technology. In those cases, the conferences have given us solid chances to broaden awareness. They've also worked well for us in terms of actually rolling the devices out at those events, so people could see them firsthand.
All right, great. Thanks, Vince. I appreciate the answers.
Hi there, guys. Thanks for taking my questions. I'm just curious about pricing and how the current pricing model works, or what you're marketing the DeepView system under, and how you arrived at that price point given that it's a new-to-market system or device. Also, is there pricing power beyond this, or any add-ons that you expect to adopt further down the road?
Luke, thanks for the question. Pricing for the device is actually something we focused on well before we obtained our FDA approval in late May. We engaged leading Deloitte Consulting, frankly a leading consulting firm, to help us with our pricing analysis. We've also been in discussions with a number of different burn centers to get KOL opinions on pricing models. We feel our pricing strategy is in line with adoption, both at leading burn centers and other smaller burn centers across the country. We think there is a compelling economic modeling here, both with length of stay reductions and with the work we've done on the reimbursement side, both for the hospital systems and with payments to physicians if we can migrate our CPT 3 coding down to a CPT 1. There are strong economic models here for the adoption of the device, not to mention for the use of the device in some of the clinical study work.
That's useful. Now, regarding the gross margin decline, I understand that's the BARDA cost-share arrangement that either is taking effect or took effect during this quarter. Does that apply only to these first 30 devices, or how do you expect gross margins to look somewhat further out?
Hi, Luke. David here. There are two separate components. The devices relate to our commercialization sales. Our gross margin for the current quarter reflects reimbursement of R&D expenses, so that's the piece covered under the BARDA cost-share. As for this current follow-on phase of that BARDA contract, that cost-share will remain in place; this quarter should be indicative of our ongoing gross margins under that contract. Again, any commercial sales will be additive and incremental in improving our gross margins going forward.
Understood. So who exactly are you going after, or what does the go-to-market sales approach look like? Is it clinicians, doctors—which people at the trauma centers, burn centers, or emergency rooms are you talking with—or are there distributor partnerships? Basically, what's the approach, and who are you sitting down with?
Luke, from where we sit—this is Vince—once again, we've worked with quite a few burn centers and many of their top burn physicians, who are genuinely key opinion leaders in this field. They're really the people championing our procurement process across many of the centers. At some centers that have had no experience with our DeepView device, it's actually been quite rewarding for us to connect with their emergency room physicians and/or their burn physicians and actually sit down and do a live demonstration in their hospital to help move the procurement process forward. Put simply, it's a relationship-based, KOL-driven initial approach across a number of different burn centers. For those with limited experience with us, it's been a real opportunity to leverage that through an on-site demonstration with many of the leaders in the burn community there and/or the trauma center, to drive that forward for us as we work through procurement.
Understood. I appreciate you taking our questions, folks.
To wrap up, I want to point out that on the commercial front we've genuinely achieved meaningful progress as we shift our business away from being a research shop toward becoming a commercial enterprise, though we're also aware that building a commercial enterprise calls for steady execution over time. What we're focused on is developing for our first customers, learning from every deployment, and putting in place the processes that can enable broader adoption throughout the United States. I want to thank our employees, our clinical collaborators, and our government partners for the work they continue to do, and our shareholders for their ongoing support while we make this transition; we're extremely excited about what lies ahead for us, and we look forward to keeping all of you apprised of the progress we make. Thank you all for your attention and your interest in our company. Have a nice evening.
That brings the conference to a close. We appreciate your joining today's presentation. You're free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Spectral AI, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Spectral AI, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.